Analyst David Risinger from Leerink Partners maintained a Hold rating on Johnson & Johnson and increased the price target to $171.00 from $153.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Risinger has given his Hold rating due to a combination of factors that reflect both positive growth prospects and existing challenges for Johnson & Johnson. The company’s recent quarterly results and increased earnings guidance indicate resilience against pressures from Stelara biosimilars, and management has expressed confidence in future growth, particularly with new products like TAR-200 for bladder cancer. However, while the revenue and earnings forecasts have been raised, there are still uncertainties, such as the outcome of the talc litigation and the implications of the One Big Beautiful Bill Act on drug pricing.
Despite these positive developments, the ongoing evaluation of legislative impacts and pending legal rulings introduce a level of uncertainty that tempers the overall outlook. As a result, while the price target has been increased, the recommendation remains at Hold, reflecting a balanced view of the potential upside and existing risks.
In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $176.00 price target.
JNJ’s price has also changed moderately for the past six months – from $147.030 to $162.980, which is a 10.85% increase.